New Microsoft Office Word Document General (2)
1 HIV/AIDS Scenario INDIA Dr Milind Kulkarni Dr DSA Karthickeyan.
UNITAID WHO EXPERT WORKING GROUP ON R&D* FINANCING Geneva, 13 January 2009 Dr. Philippe Douste-Blazy, Chairman, UNITAID.
Development of Pediatric ARV Drugs – FDA Perspective Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products U.S. Food and Drug Administration.
Toxicity of stavudine- and nevirapine-containing antiretroviral treatment regimens: incidence and risk factors after 3 years in a large cohort in Rwanda.
Hepatitis web study Hepatitis web study Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial (Arms 12-17 & 22) Phase 2 Treatment Naïve.
Dr.s.s amended schedule y
Regulation on new drugs
Control of communicable diseases
Ueda2015 patient centered approach dr.mesbah
Snehal Khedkar | April 2008 1 |1 | Pharmaceutical Development with Focus on Paediatric formulations WHO/FIP TRAINING WORKSHOP Hyatt Regency Hotel Sahar.
Historical Overview of Pharmaceutical Industry and Drug Regulatory Affairs 2167 7689.S11 002
